Therapeutic Suppression of Specific Immune Responses by Administration of Oligomeric Forms of Antigen of Controlled Chemistry

The method and construct used to reduce undesired antibody response in a mammal by administering a non-immunogenic construct of which contains at least two copies of a B cell membrane immunoglobulin receptor epitope bound to a pharmaceutically acceptable non-immunogenic carrier. This directly binds to the B cell membrane immunoglobulin receptors but fails to form an immunon. Description (Set) Proposed Use (Set) This invention is available for licensing for use in treatment of all diseases and conditions with the exception of cancer, antiphospholipid syndrome, xenografts, and lupus

Patent (Set) 7,083,959; 5,126,131; 5,370,871; 6,375,951; 6,340,460; 6,022,544

Patents:
US 7,083,959

Inventor(s): Dintzis, Renee Z.

Type of Offer: Licensing



« More Pharmaceutical Patents

---